IN8bio (INAB)
(Delayed Data from NSDQ)
$1.04 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INAB 1.04 0.00(0.00%)
Will INAB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INAB
Here's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom Fisher
IN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden Cross
INAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know
Other News for INAB
Promising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR Platform
12 Health Care Stocks Moving In Friday's After-Market Session
ATUS, ATHE and GRFS among pre-market losers
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), PainReform (PRFX) and IN8bio (INAB)
Analysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON) and IN8bio (INAB)